Moderna stock jumped 131%A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.Decrypt · 19 Aug 2026 · 16:54 UTC · read it at the source following positive Phase 3 results for its cancer vaccine, which outperformed standard-of-care treatment in the trial.

The surge cost short sellers $4.8 billionA Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.Decrypt · 19 Aug 2026 · 16:54 UTC · read it at the source in losses, according to Decrypt.

Sources: MarketWatch, Decrypt

This article is for information only and is not financial advice.